With reference to the press release previously sent out during the day regarding the termination of GHP's agreement in the United Arab Emirates, we hereby clarify that the Group's overall goal to achieve an average organic growth of 15% per year over a three-year period and to achieve an EBIT margin of at least 7%, remain unchanged.
GHP has a very solid core business with over 20 leading clinics in the Nordic region. We see a great demand for high-quality specialist healthcare, which means that we continue the successful work of expanding our network of Nordic clinics, while at Vårdsamverkan we develop new, modern forms of collaboration for the insurance company market and occupational health care. The termination of our agreement in the United Arab Emirates next year does not affect our goal of high growth and strengthened profit margins, says Daniel Öhman, CEO of GHP.
For those of you who want to know more about what the changes around SKMCA mean, GHP invites you to a conference call tomorrow, 13/9, at 13.00. More information on how to join the conference call will be available on GHP's IR page tomorrow, no later than at 11.00.
Daniel Öhman, CEO
Tel: +46 (0) 708-55 37 07
GHP is an internationally active health care provider that operates specialist clinics in a select number of diagnostic areas through the application of a business model that is unique in the health care industry, where leading doctors and medical staff become partners and shareholders. Each clinic specialises in a particular patient group, and this leads to increased efficiency and higher quality. This is the cornerstone of GHP's business philosophy - 'Quality through specialisation'. GHP shares are traded on the Small Cap list of Nasdaq Stockholm under the ticker symbol 'GHP'.
GHP Specialty Care AB published this content on 12 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 September 2021 16:11:00 UTC.